Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
Flash
09:15
BIT: Circle drops 28%, valuation returns to the watch range
Odaily reported that BIT released today's chart, stating that in our report on February 25, we pointed out that when the share price of a certain exchange fell to around $63, short positions were crowded, and covering them could drive a rapid rebound in the share price. A few weeks later, the stock briefly rose to $125. In the daily report on March 16, we judged that this round of short squeeze had basically been released. Subsequently, the share price has fallen by about 28% in total, confirming this assessment. CLARITYAct has recently seen a key development: a compromise draft proposes to limit platforms from providing yield on idle token balances. For one exchange, the expansion space for certain interest-paying products may narrow; however, once the regulatory framework is finalized, USDC's compliant status will actually become clearer. The plan has not yet been finalized; coupled with slowed stablecoin growth and reduced market activity, there is a lack of clear short-term catalysts. According to our fundamental framework, as the share price gradually approaches below $80, the valuation of a certain exchange has once again entered a noteworthy range.
09:15
U.S. stocks move: BullFrog AI continues to rise more than 16% in pre-market trading, partnering with a global top 5 pharmaceutical company to develop a new antidepressant drug
Glonghui, March 31|BullFrog AI (BFRG.US), which surged more than 106% yesterday, continued to rise over 16% in pre-market trading to $1.22. In the news, Bullfrog AI Holdings’ share price soared on Monday after the company reached a commercial agreement with a top-five global pharmaceutical company to identify and prioritize therapeutic targets for major depressive disorder. The agreement covers the use of the company’s proprietary bfLEAP platform to identify and prioritize new drug targets in major depressive disorder (MDD), thereby accelerating the partner's drug discovery and clinical development programs. This collaboration is an important step for the company and may bring new treatment approaches to key areas of healthcare.
09:12
Eurozone inflation in March surpasses 2% target, leaving the European Central Bank in a dilemma
PANews reported on March 31 that Eurozone inflation surged this month and exceeded the European Central Bank's 2% target, driven by a sharp increase in oil and gas prices. This has intensified the policy dilemma: high energy costs are weighing on economic growth while also raising the risk of triggering an inflationary spiral. Data released by the EU statistics agency on Tuesday shows that the overall inflation rate in the Eurozone rose from 1.9% in the previous month to 2.5% in March, with energy costs up by 4.9%. If companies pass on higher costs to their selling prices and workers demand higher wages due to a decline in real disposable income, rapidly rising energy inflation could easily spread. ECB President Lagarde stated last week that if the central bank does nothing, the public may begin to question its determination to fight inflation. Even when inflation shocks are significant but short-lived, this would strengthen the case for interest rate hikes. Financial markets currently expect the ECB to raise rates three times this year, with the first likely in April or June. Although some officials, including Bundesbank President Nagel, say a rate hike as early as April is also an option, others such as Executive Board member Schnabel have warned against acting hastily.
News